Related Experiment Video
Updated: Oct 18, 2025

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Niclosamide and Pyrvinium Are Both Potential Therapeutics for Osteosarcoma, Inhibiting Wnt-Axin2-Snail Cascade
Young Yi1, Young Mi Woo2, Kyu Ho Hwang2
1Department of Orthopedics, Inje University Seoul Paik Hospital, Seoul 04551, Korea.
Abstract:
Osteosarcoma, the most common primary bone malignancy, is typically related to growth spurts during adolescence. Prognosis is very poor for patients with metastatic or recurrent osteosarcoma, with survival rates of only 20-30%. Epithelial-mesenchymal transition (EMT) is a cellular mechanism that contributes to the invasion and metastasis of cancer cells, and Wnt signaling activates the EMT program by stabilizing Snail and β-catenin in tandem. Although the Wnt/Snail axis is known to play significant roles in the progression of osteosarcoma, and the anthelmintic agents, niclosamide and pyrvinium, have been studied as inhibitors of the Wnt pathway, their therapeutic effects and regulatory mechanisms in osteosarcoma remain unidentified. In this study, we show that both niclosamide and pyrvinium target Axin2, resulting in the suppression of EMT by the inhibition of the Wnt/Snail axis in osteosarcoma cells. Axin2 and Snail are abundant in patient samples and cell lines of osteosarcoma. The treatment of niclosamide and pyrvinium inhibits the migration of osteosarcoma cells at nanomolar concentrations. These results suggest that Axin2 and Snail are candidate therapeutic targets in osteosarcoma, and that anthelminthic agents, niclosamide and pyrvinium, may be effective for osteosarcoma patients.
Insights
Anthelmintic agents niclosamide and pyrvinium suppress osteosarcoma (bone cancer) cell migration by inhibiting the Wnt/Snail pathway. These drugs target Axin2, offering potential new treatments for osteosarcoma patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma is a primary bone cancer with poor prognosis, especially in metastatic or recurrent cases.
- Epithelial-mesenchymal transition (EMT), driven by Wnt signaling, promotes cancer cell invasion and metastasis.
- The Wnt/Snail axis is implicated in osteosarcoma progression, but therapeutic targets remain elusive.
Purpose of the Study:
- To investigate the therapeutic effects and regulatory mechanisms of niclosamide and pyrvinium in osteosarcoma.
- To identify the role of Axin2 and Snail in osteosarcoma progression and metastasis.
Main Methods:
- Utilized osteosarcoma cell lines and patient samples.
- Administered niclosamide and pyrvinium to assess their impact on cellular mechanisms.
- Measured cell migration and analyzed the Wnt/Snail signaling pathway and Axin2 expression.
Main Results:
- Niclosamide and pyrvinium were found to target Axin2 in osteosarcoma cells.
- These agents suppressed EMT by inhibiting the Wnt/Snail axis.
- Axin2 and Snail were notably abundant in osteosarcoma samples.
- Niclosamide and pyrvinium inhibited osteosarcoma cell migration at nanomolar concentrations.
Conclusions:
- Axin2 and Snail are potential therapeutic targets for osteosarcoma.
- Anthelmintic agents niclosamide and pyrvinium demonstrate therapeutic potential for osteosarcoma treatment.
Related Concept Videos
Non-Canonical Wnt Signaling Pathways
Canonical Wnt Signaling Pathway
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Abnormal Proliferation

